Objective To investigate the clinical curative effect and side effect of thalidomide combined with VAD on treatment of multiple myeloma. Method 47 cases of multiple myeloma patients were randomly divided into VAD group (23 cases): vincristine + doxorubicin + dexamethasone; combined treatment group(24 cases) I VAD+thalidomide. Results The total effective rate of combined treatment group (83.3%) was better than the control group (60.9%) (P<0. 05). After treatment, M protein, myeloma cells and β2-microglobulin decreased significantly (P< 0. 05), decreased more significantly in combined treatment group (P<0. 05). The hemoglobin of two groups increased significantly (P<0. 05), increased more significantly in combined treatment group (P<0. 05), while the side effects were tolerable. Conclusion Thalidomide incorporation with VAD applied in multiple myeloma has merits such as less side effects, good tolerance, convenient administration and significant curative effect.%目的 探讨沙利度胺联合VAD方案治疗多发性骨髓瘤(MM)的临床疗效及不良反应.方法 47例多发性骨髓瘤患者随机分为VAD组(23例):长春新碱+阿霉素+地塞米松；联合治疗组(24例):沙利度胺+VAD方案.结果 联合治疗组总有效率为83.3％,明显优于对照组总有效率(60.9％,P＜0.05);两组治疗后M蛋白、骨髓瘤细胞、p2-微球蛋白均明显下降(P＜0.05),联合治疗组下降更为明显(P＜0.05)；两组患者血红蛋白明显上升(P＜0.05),联合治疗组上升更为明显(P＜0.05).副反应程度均可耐受.结论 沙利度胺联合VAD方案治疗MM具有副作用少、耐受性好、给药方便、疗效明显的优点,值得临床推广应用.
展开▼
